Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06190652

Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC. — REICRAE  

Metastatic Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:
Real-world Experience of Immunotherapy Plus Chemotherapy as First-line Treatment With or Without Radiotherapy for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China

Clinical Trial Summary

This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.

Clinical Trial Description

This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (ESCC) patients who were treated with chemotherapy combined with immunotherapy as 1st line treatment at approximately 5 institutions. The patients should have received at least 1 cycle of immunotherapy and chemotherapy with or without radiotherapy. Based on these data, overall survival (OS), progression free survival (PFS) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06190652
Study type Observational
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Completed
Phase
Start date October 13, 2018
Completion date December 4, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01142388 - Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06138028 - Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer Phase 2/Phase 3
Recruiting NCT05512520 - Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003） Phase 2
Active, not recruiting NCT05142709 - Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Not yet recruiting NCT05522894 - AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC Phase 2
Completed NCT01472419 - Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma N/A
Enrolling by invitation NCT03800953 - The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Recruiting NCT04949256 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) Phase 3
Recruiting NCT05978193 - Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05760391 - A Study of IO Plus Radiotherapy in Patients With Advanced ESCC. N/A
Active, not recruiting NCT04460937 - Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Phase 1